Administration of JAK inhibitors in patients with RA was associated with elevated risk of major adverse CVD events, cancers and several adverse events compared to a TNF inhibitor,56 although the exact mechanisms of action on the cardiovascular system remain under investigation.57 Here, TNF is linked to cancer.